Key result
Antidepressants reduce depression and cut MI recurrence ~21% without increasing adverse cardiac events.
Why the study?
To summarize available data and evaluate whether antidepressants are effective and well-tolerated for treating post-myocardial infarction-associated depression.
Do antidepressants improve depression scores and reduce adverse cardiac events in patients with post-myocardial infarction depression?
Meta-Analysis (n=15,719)
Do antidepressants improve depression scores and reduce adverse cardiac events in patients with post-myocardial infarction depression?
Antidepressants effectively improve depressive symptoms and may reduce the risk of MI recurrence in patients with post-MI depression without increasing adverse cardiac events.
Supports antidepressant use in post-MI depression to ease symptoms and lower recurrence risk without cardiac harm; reinforces RCT meta-analytic evidence.
OBJECTIVE: This study aimed to summarize the available data and assess whether antidepressants are effective and well-tolerated in the treatment of post-myocardial infarction (MI)-associated depression. MATERIALS AND METHODS: A comprehensive search of public databases (PubMed, Embase, Web of Science, Ovid, EBSCO, and the Cochrane Library) was conducted for publications on interventions for post-MI depression before October 2024. Keywords included post-myocardial infarction depression, antidepressants, myocardial infarction, and depression. Pooled data were analyzed using Stata software. RESULTS: A total of twelve studies were included. At baseline, no significant difference was observed in depression severity between the antidepressant treatment and control groups (pooled SMD = -0.022, 95% CI: -0.087-0.044). Antidepressant treatment significantly reduced depression scores after long-term follow-up (pooled SMD = -1.023, 95% CI: -1.671- -0.375). The incidence of adverse cardiac events was not significantly higher in the treatment group compared to the control group (pooled HR = 0.893, 95% CI: 0.793-1.005). Antidepressants did not increase the risk of all-cause mortality (pooled HR = 0.957, 95% CI: 0.699-1.311), and there was no significant difference in the risk of rehospitalization for heart disease (pooled HR = 1.070, 95% CI: 0.820-1.398). Antidepressant treatment was associated with a reduced risk of MI recurrence (pooled HR = 0.787, 95% CI: 0.693-0.894) and revascularization procedures (pooled HR = 0.858, 95% CI: 0.755-0.975). Moderate-certainty evidence (GRADE assessment) supports antidepressant efficacy in improving depressive symptoms, while low-certainty evidence suggests potential cardiac risk reduction. CONCLUSION: This meta-analysis demonstrates that antidepressants are effective and well-tolerated in the treatment of post-MI depression. Antidepressants can improve depressive symptoms without adversely affecting long-term prognosis. The clinical application of these findings should consider the moderate certainty for symptom improvement and low certainty for MI recurrence benefits.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2025) conducted a meta-analysis in Post-myocardial infarction associated depression (n=15,719). Antidepressants (SSRIs, TCAs, mirtazapine) vs. Conventional treatment excluding antidepressants was evaluated on Depression severity after long-term follow-up (SMD -1.023, 95% CI -1.671– -0.375). Antidepressant treatment significantly reduced depression scores (SMD -1.023) and the risk of myocardial infarction recurrence (HR 0.787) without increasing adverse cardiac events or all-cause mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: